Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) – Research analysts at William Blair issued their Q1 2023 earnings estimates for shares of Henry Schein in a research report issued on Tuesday, May 3rd. William Blair analyst J. Kreger anticipates that the company will post earnings of $1.36 per share for the quarter. William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for Henry Schein’s Q2 2023 earnings at $1.30 EPS, Q3 2023 earnings at $1.27 EPS, Q4 2023 earnings at $1.26 EPS, FY2024 earnings at $5.57 EPS, FY2025 earnings at $5.95 EPS and FY2026 earnings at $6.35 EPS.
Henry Schein (NASDAQ:HSIC – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported $1.30 EPS for the quarter, beating the Zacks’ consensus estimate of $1.19 by $0.11. Henry Schein had a net margin of 5.09% and a return on equity of 15.84%. The company had revenue of $3.18 billion for the quarter, compared to analyst estimates of $3.12 billion. During the same period in the prior year, the firm posted $1.24 EPS. The company’s quarterly revenue was up 8.7% on a year-over-year basis.
NASDAQ:HSIC opened at $86.42 on Thursday. The firm’s fifty day moving average is $87.30 and its 200-day moving average is $80.45. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.86 and a current ratio of 1.67. Henry Schein has a 52 week low of $70.25 and a 52 week high of $92.68. The firm has a market cap of $11.93 billion, a P/E ratio of 18.79, a P/E/G ratio of 1.40 and a beta of 0.75.
In other Henry Schein news, EVP Mark E. Mlotek sold 24,075 shares of the stock in a transaction dated Thursday, February 24th. The shares were sold at an average price of $82.99, for a total transaction of $1,997,984.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Scott Philip Serota bought 1,000 shares of the business’s stock in a transaction on Friday, March 4th. The shares were acquired at an average price of $85.87 per share, with a total value of $85,870.00. The disclosure for this purchase can be found here. Corporate insiders own 1.00% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in HSIC. Farmers & Merchants Investments Inc. purchased a new stake in Henry Schein in the fourth quarter valued at approximately $32,000. Covestor Ltd purchased a new stake in Henry Schein in the fourth quarter valued at approximately $35,000. National Bank of Canada FI purchased a new stake in Henry Schein in the fourth quarter valued at approximately $42,000. CI Investments Inc. purchased a new stake in Henry Schein in the third quarter valued at approximately $46,000. Finally, Quent Capital LLC purchased a new position in shares of Henry Schein during the fourth quarter worth approximately $47,000. Institutional investors own 94.30% of the company’s stock.
Henry Schein Company Profile (Get Rating)
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.